Search Results for: Marc Tessier-Lavigne
Tessier-Lavigne, Rockefeller president and head of the Laboratory of Brain Development, and Jeffrey M. Friedman head of the Laboratory of Molecular Genetics, were elected to the honorary society and independent policy research center along with 198 other leaders in science, art, academia and the civic, corporate and philanthropic arenas. The current membership includes some 250 Nobel laureates and more than 60 Pulitzer Prize winners, and 23 other Rockefeller University faculty members are fellows.
President Marc Tessier-Lavigne will receive the Henry G. Friesen International Prize in Health Research, established by the Friends of Canadian Institutes of Health Research in collaboration with the Canadian Academy of Health Sciences to recognize exceptional innovation by a visionary health leader of international stature.
A world leader in the study of brain development, Tessier-Lavigne has pioneered the identification of the molecules that direct the formation of connections among nerve cells to establish neuronal circuits in the mammalian brain and spinal cord. Tessier-Lavigne is among 65 new members and five foreign associates elected to the Institute this year. More »
Rockefeller University’s President will receive the Memorial Sloan-Kettering Medal for Outstanding Contributions to Biomedical Research at MSKCC’s 2011 Academic Convocation. More »
Marc Tessier-Lavigne, a leading neuroscientist and the former chief scientific officer of Genentech, takes over as president of The Rockefeller University today, replacing Paul Nurse, who has left to become president of the Royal Society in London. More »
The university’s Board of Trustees has elected Tessier-Lavigne to succeed Paul Nurse on March 11, 2011. A leader in the study of brain development, he is currently executive vice president for research and chief scientific officer at Genentech, one the world’s leading biotech companies. More »
The award recognizes Fuchs’s contributions to our understanding of skin biology and skin stem cells, including discoveries that have led to advancements in treating skin cancer and severe burns.
Allis’s discovery that chemical “tags” bind to specific sections of histone proteins in order to activate or silence nearby genes has ignited the field of epigenetics, a relatively new area of study which explores the inheritance of physical changes that cannot be traced back to mutations in the DNA sequence. The Japan Prize, worth approximately half a million dollars, is among the most prestigious prizes in science. More »
The fund, to be known as the Robertson Therapeutic Development Fund in honor of a $25 million gift from the Robertson Foundation, will provide Rockefeller scientists with resources required to take exceptionally promising basic research initiatives through the steps that lead to breakthrough medications, new diagnostic tests or other clinical innovations. More »
Accomplished Scientist and Entrepreneur Selected to Lead Tri-Institutional Therapeutics Discovery Institute
NEW YORK (Dec. 5, 2013) – Michael A. Foley, Ph.D., has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan-Kettering Cancer Center that … More »
An accomplished chemist and entrepreneur with more than 25 years of industry and academic experience, Foley has been named director of a pioneering early stage drug discovery initiative formed jointly with Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center formed in October. More »
Neuron online: November 6, 2013 Regulation of axon degeneration after injury and in development by the endogenous calpain inhibitor calpastatin Jing Yang, Robby M. Weimer, Dara Kallop, Olav Olsen, Zhuhao Wu, Nicolas Renier, Kunihiro Uryu and Marc Tessier-Lavigne
The Tri-Institutional Therapeutics Discovery Institute, Inc. is launched by Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College, and a pioneering partnership is formed with Takeda Pharmaceutical Company. More »
Tri-Institutional Therapeutics Discovery Institute, Inc. Launched by Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College, and Partnership Formed with Takeda
Pioneering Collaboration with Research-Based Global Pharmaceutical Company to Conduct Early-Stage Drug Discovery New Powerhouse for Therapeutic Research Founded with $20 Million in Generous Support from Lewis Sanders and Howard Milstein NEW YORK (Oct. 1, 2013) ─ Memorial Sloan-Kettering Cancer Center, The … More »
Sebastian Klinge has dedicated his career to understanding the ribosome, with a particular emphasis on its atomic structure and the process by which it forms in the cell. Klinge is the first faculty member to be recruited to the university under its 2012 strategic plan; he was appointed assistant professor in June and will open his lab, to be called The Laboratory of Protein and Nucleic Acid Chemistry, on September 15. More »
U.S. university heads in Israel to establish academic ties “I was amazed to watch two paraplegics walk independently using the ReWalk robotic device and moved when they showed how leaving their wheelchairs has transformed their lives,” said Rockefeller University … More »
Rockefeller president joins U.S. university leaders in Israel to explore collaborative opportunities
Rockefeller’s president, Marc Tessier-Lavigne, will join several U.S. university leaders in Israel this week to explore opportunities for collaborations with Israeli institutions in areas such as brain science, environmental sustainability, biotechnology, diversity and women’s leadership. The visit has been arranged by Project Interchange, a non-profit educational institute of the American Jewish Committee, which is an advocacy group based in New York. More »
Fisher is a postdoc in James Hudspeth’s Laboratory of Sensory Neuroscience studying the biophysics and neurophysiology of the auditory system. He is one of seven winners of the prize, which is given to faculty and postdocs in the tri-state area. More »
Young and two colleagues will be awarded the 2013 Shaw Prize in Life Science and Medicine, worth $1 million. Established in 2002, the Shaw Prize honors individuals who have achieved breakthroughs in academic and scientific research or applications and whose work has resulted in a positive and profound impact on humanity. More »